VHIO Seeks a Postdoctoral Fellow to Join its Tumor Immunology & Immunotherapy Group
Application deadline: 31/03/2019 (Review of applications will commence immediately)
The Vall d´Hebron Institute of Oncology´s (VHIO) Tumor Immunology and Immunotherapy Group, headed by Dr. Alena Gros, is currently recruiting for a Postdoctoral Fellow. The successful candidate will be part of the scientific team and will be directly involved in the characterization of the personalized repertoire of tumor–reactive and mutation-specific lymphocytes in patients with cancer.
A highly motivated, team-oriented individual with previous experience in a biomedical research laboratory and highly skilled in cell/tissue processing, multi-color flow cytometry and molecular biology. The ideal candidate should be familiar with ELISA, ELISpot, flow-cytometry and would be comfortable working with human blood and tissues. Previous experience working with T cells will be favorably considered.
Candidates must submit a curriculum vitae and letter of intent addressed to Dr. Alena Gros using the form or via email to: firstname.lastname@example.org, adding “Ref. 06/2019” in the subject line.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: http://www.vhio.net.